A New Veterinary Eye Therapy With a Novel Mechanism of Action
OcuPaws is a dual-action, host-targeted eye treatment for animal infections and injuries, antibiotic-free, IP-protected, and ready to de-risk early investment. Register Your InterestWhat’s Missing in the Current Market
Limited Innovation in the Veterinary Ophthalmology Space
Despite growing demand for safer, simpler treatment options:
Few Differentiated Products
Most available options are off-patent or generic, offering limited clinical or commercial distinction.
Stagnant R&D Pipeline
Antibiotic innovation in animal health has slowed, leaving few new tools to address AMR challenges.
Weak IP Protection
Lack of strong, defensible IP limits exclusivity and long-term commercial value.
High Development Risk
Bringing new compounds to market is costly and time-intensive, with limited early-stage validation in this space.
A Differentiated, De-risked Asset for Veterinary Ophthalmology
OcuPaws is being developed as a novel, dual-action, non-antibiotic treatment for animal eye infections – with built-in clinical, commercial, and strategic advantages:
Novel Mechanism of Action
Targets the host to prevent bacterial adhesion and promote healing – without relying on antibiotic killing.
Strong IP Position
Protected by composition-of-matter and method-of-use claims, offering potential for exclusivity in a low-competition space.
Early Validation Complete
Lead compound identified with TRL 4 for ophthalmic use – reducing technical risk at the licensing stage.
Commercial Flexibility
Suitable for use in pets or livestock, alone or alongside antibiotics – with clear relevance to AMR strategy and market demand.
Join our research network
If This Sounds Relevant — We Want to Hear From You
We’re developing OcuPaws to make eye care simpler, safer, and more effective for vets, animals, and owners. If you’re interested, leave your details below.